# US 2024/0189311 A1 · Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189311 A1
- Document ID: US20240189311A1
- Status: Published application
- Kind: A1
- Application number: 18/277,851
- Filed: 2022-02-18
- Published: 2024-06-13
- Earliest claimed: 2021-02-18
- Applicants: Newamsterdam Pharma B.V.
- Inventors: Johannes Jacob Pieter Kastelein; Marc Ditmarsch; Michael Harvey Davidson
- Web page: https://patentgrep.com/patent/US20240189311A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition and a therapeutic combination comprising obicetrapib and ezetimibe, which may be used in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia and wherein said subjects are partially or completely intolerant to statins.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method of treating a subject suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia, the method comprising:
administering to the subject a therapeutically effective amount of (i) obicetrapib, or a pharmaceutically acceptable salt or solvate thereof, and (ii) ezetimibe, or a pharmaceutically acceptable salt or solvate thereof,
wherein the subject is partially or completely intolerant to statins.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the subject suffers from hyperlipidemia or mixed dyslipidemia.

### Claim 37 (depends on 35)

The method according to claim 35, wherein the subject has an increased risk for hyperlipidemia or mixed dyslipidemia.

### Claim 38 (depends on 35)

The method according to claim 35, wherein the subject is orally administered between 1 to 10 mg per day obicetrapib and between 5 to 20 mg ezetimibe per day.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the subject is orally administered (i) 5 mg obicetrapib per day and 10 mg ezetimibe per day or (ii) 10 mg obicetrapib per day and 10 mg ezetimibe per day.

### Claim 40 (depends on 35)

The method according to claim 35, wherein apolipoprotein B (ApoB) concentration in the blood of the subject is reduced.

### Claim 41 (depends on 35)

The method according to claim 35, wherein LDL-C concentration in the blood of the subject is reduced.

### Claim 42 (depends on 35)

The method according to claim 35, wherein the reduction of LDL-C levels by the combination of obicetrapib and ezetimibe is no less than the LDL-C reduction by the same dose of obicetrapib administered as monotherapy.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the LDL-C reduction by a daily dose of 5 mg obicetrapib when administered with 10 mg ezetimibe is no less than the LDL-C reduction by a daily dose of 5 mg obicetrapib administered as monotherapy.

### Claim 44 (depends on 42)

The method according to claim 42, wherein the relative LDL-C reduction by a daily dose of 10 mg obicetrapib when administered as the pharmaceutical composition with 10 mg ezetimibe is similar to the relative LDL-C reduction by a daily dose of 10 mg obicetrapib administered as monotherapy.

### Claim 45 (depends on 35)

The method according to claim 35, wherein obicetrapib and ezetimibe are administered in a single oral dosage form.

### Claim 46 (depends on 45)

The method according to claim 45, wherein the oral dosage form is an oral fixed dose combination.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the oral fixed dose combination is a solid dosage form.

### Claim 48 (depends on 47)

The method according to claim 47, wherein the solid dosage form is a capsule or tablet.

### Claim 49 (depends on 35)

The method according to claim 35, wherein the method reduces the risk for major adverse cardiovascular events.

### Claim 50

A method of treating a subject suffering from cardiovascular disease or having an increased risk for cardiovascular disease, the method comprising:
administering to the subject a therapeutically effective amount of (i) a CETP-inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and (ii) ezetimibe, or a pharmaceutically acceptable salt of solvate thereof,
wherein the subject is partially or completely statin intolerant.

### Claim 51 (depends on 50)

The method of claim 50, wherein the CETP-inhibitor is obicetrapib.

### Claim 52

A method for reducing the risk for cardiovascular events in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of (i) obicetrapib, or a pharmaceutically acceptable salt or solvate thereof, and (ii) ezetimibe, or a pharmaceutically acceptable salt or solvate thereof,
wherein the subject is partially or completely statin intolerant.
